HealthCare Royalty Partners

Name

HealthCare Royalty Partners

Legal name

HealthCare Royalty Management, LLC

Website

https://hcrx.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

HealthCare Royalty Partners (HCRx) is a private investment firm that acquires royalty interests and provides structured financing to commercial-stage biopharmaceutical companies, universities, and inventors in exchange for non-dilutive capital.

Ownership category

akta.pro rank

Headquarters

HQ city

Stamford

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Royalty Payments: HCRx generates revenue by acquiring royalty interests in commercialized biopharmaceutical products. They receive ongoing royalty payments based on product sales, typically structured with caps and tiered rates.
2. Interest Income on Structured Financing: The company provides debt and credit facilities to biopharma companies, earning interest payments on the capital advanced. Terms include interest-only periods and fixed repayment schedules.
3. Warrant Gains: As part of financing agreements, HCRx receives warrants to purchase shares of financed companies, which can generate returns upon exercise or sale.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

HealthCare Royalty Partners (HCRx) is a private investment firm that acquires royalty interests and provides structured corporate financing to commercial-stage biopharmaceutical companies, universities, research institutions, and inventors. The firm purchases full or partial royalty rights and extends debt-like credit facilities tied to product sales, enabling counterparties to raise non-dilutive capital. HCRx has committed over $7 billion across more than 110 biopharmaceutical products and manages approximately $3 billion in assets.

Product overview

HealthCare Royalty (HCRx) is a royalty acquisition company providing creative capital solutions to biopharmaceutical companies. Founded in 2006 and majority owned by KKR since July 2025, the firm offers two primary product lines: Royalty Monetization (full or partial sale of royalty rights) and Corporate Financing (structured credit and royalty-based financing). HCRx has committed over $7 billion across more than 110 biopharmaceutical products and manages approximately $3 billion in assets. Recent major transactions include AD109 financing for Apnimed (up to $150M), BEYONTTRA European royalty monetization for BridgeBio ($300M), JNJ-1900 royalty for Nanobiotix (up to $71M), REGENXBIO royalty bond (up to $250M), YUTREPIA financing for Liquidia (up to $200M), ENBUMYST acquisition financing for Esperion ($25M), and Modeyso royalty monetization for Oncoceutics. The portfolio spans over 30 therapeutic areas including oncology, cardiovascular, rare diseases, and gene therapies, with products such as ZOLGENSMA, VIMPAT, ADYNOVATE, MOVANTIK, GOOFICE, VAFSEO, and ANDEXXA.

Differentiator

Problem solved

Functional benefit

Products and services

• Royalty Monetization HCRx's core service enabling biopharmaceutical companies to sell full or partial royalty rights from license agreements in exchange for upfront capital, allowing sellers to eliminate or delay equity dilution while raising non-dilutive funds.
• Corporate Financing Structured financing solutions including debt-like corporate financing with defined fixed repayment of interest and principal, and royalty-based financing where repayment is variable and linked to product sales or company revenue.
• Synthetic Royalty Financing A hybrid financing structure combining senior secured debt with synthetic royalty components, where repayment aligns with product sales performance while often including fixed repayment schedules and interest-only periods.

Quantifiable outcome

• Over $7 billion committed in capital across more than 110 biopharmaceutical products
• +3 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered minor, core and secondary.

• Jazz PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 22 April 2026Jazz Pharmaceuticals commercializes Modeyso (dordaviprone), an FDA-approved treatment for H3 K27M-mutant diffuse midline glioma. HCRx acquired undisclosed percentage of royalties on Modeyso commercial sales from former Oncoceutics securityholders.
• ApnimedcoreStrategic or Co-development Partner · 6 April 2026Senior secured credit facility of up to $150 million to support commercial launch of AD109 for obstructive sleep apnea. Includes $50 million at closing, $50 million upon FDA approval, and $50 million upon sales milestone, plus low single-digit synthetic royalty on net sales.
• Heidelberg PharmasecondaryStrategic or Co-development Partner · 9 March 2026Amendment to existing royalty purchase agreement bringing in Soleus Capital as new participant for partial monetization of future royalties on Telix Pharmaceuticals' imaging diagnostic agent TLX250-Px. Heidelberg Pharma receives $20 million upfront and additional $25 million upon FDA approval.
• Esperion TherapeuticscoreStrategic or Co-development Partner · 3 March 2026Royalty monetization of Japanese royalties with HCRx and Athyrium Capital Management supporting Esperion's acquisition of Corstasis Therapeutics and Enbumyst cardiovascular franchise expansion.
• ADC TherapeuticscoreStrategic or Co-development Partner · 23 February 2026Amendment to royalty purchase agreement reducing change-of-control payment from $750 million to $150 million through 2027. HCRx received warrants for approximately 9.8 million shares at $3.81 per share, exercisable until December 2030.
• Atara BiotherapeuticssecondaryStrategic or Co-development Partner · 23 February 2026Amendment to agreement extending due date for $9 million milestone payment from June 2026 to January 2028. Atara also issued warrant to HCRx for stock purchase.
• NanobiotixcoreStrategic or Co-development Partner · 31 October 2025Royalty monetization agreement providing up to $71 million in non-dilutive capital to Nanobiotix for development of JNJ-1900 (NBTXR3), a cancer nanotherapy. HCRx receives capped portion of milestones and royalties on sales, with repayment from defined portion of royalties on first $1 billion of net sales.
• BridgeBio PharmacoreStrategic or Co-development Partner · 30 June 2025$300 million partial capped monetization of BEYONTTRA European royalties with HCRx and Blue Owl Capital. Transaction monetizes 60% of BridgeBio's European royalties on first $500 million of annual net sales.
• REGENXBIOcoreStrategic or Co-development Partner · 19 May 2025Non-dilutive limited recourse royalty bond agreement of up to $250 million monetizing anticipated royalties from ZOLGENSMA, RGX-121, RGX-111, and NAV Technology Platform licensees. $150 million secured at closing with additional tranches.
• Liquidia CorporationcoreStrategic or Co-development Partner · 18 March 2025Sixth amendment providing up to $100 million additional financing in three tranches for YUTREPIA and L606 development. $25 million at closing, $50 million upon first commercial sale, and $25 million upon aggregate net sales exceeding $100 million.

Scale indicators6 records

Recent moves1 record

Expansion highlights6 records

Broad incumbents

• Baker Bros. Advisors: Biotech-focused long-only investment manager with deep relationships across biopharma. While primarily equity-focused, Baker Bros.' scale and network make it a comparable incumbent in the broader biopharma capital ecosystem where HCRx operates.

Emerging players

• OrbiMed: Healthcare-dedicated investment firm with private credit, royalty, and equity strategies across biopharmaceuticals, medical devices, and diagnostics. OrbiMed's structured credit activities overlap with HCRx's biopharma financing focus.
• HealthCor Family Office: Healthcare-focused investment firm providing structured debt, royalty financing, and equity capital to commercial-stage biopharmaceutical companies, with significant overlap in target customers and structures.
• Perceptive Advisors: Biotech-focused investment manager with credit and structured financing strategies that finance commercial-stage biopharmaceutical companies through royalty and debt structures comparable to HCRx.
• Innovatus Capital Partners: Specialty finance firm with a life sciences strategy that provides structured financing, royalty monetization, and credit facilities to biopharmaceutical companies — a directly comparable business model to HCRx.
• Soleus Capital: Biopharma-focused investment manager specializing in structured debt and royalty financing for commercial-stage and late-stage therapeutics companies. Soleus recently participated in a Heidelberg Pharma royalty alongside HCRx, evidencing direct overlap in deal sourcing.

Direct peers

• Royalty Pharma: The largest pure-play biopharmaceutical royalty buyer and the closest direct competitor to HCRx. Royalty Pharma acquires royalty interests in approved and late-stage drugs and offers capital to biotechs in structures highly comparable to HCRx's royalty monetization product.
• Deerfield Management: Healthcare-focused investment firm providing structured debt, royalty financing, and equity capital to biopharmaceutical and medical device companies. Deerfield operates a similar model to HCRx across biopharma structured credit and royalty monetization.
• Athyrium Capital Management: Specialty healthcare-focused investment manager that provides structured capital, royalty financing, and credit solutions to biopharmaceutical companies. Athyrium has co-invested with HCRx (e.g., on the Esperion/Enbumyst financing) and competes directly for the same biopharma structured-finance mandates.
• Pharmakon Advisors (BioPharma Credit): Manages the BioPharma Credit funds and provides non-dilutive structured debt to commercial-stage and late-stage biopharmaceutical companies. The closest competitor in the biopharma royalty and senior-secured credit space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/healthcare-royalty-partners
• YouTubeyoutube.com/channel/UC5ZpB8WRoCvZXq7Yf6P-j9A

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments36 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HealthCare Royalty Partners